These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7053862)

  • 41. Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system.
    Lokich J; Bothe A; Zipoli T; Green R; Sonneborn H; Paul S; Philips D
    J Clin Oncol; 1983 Jan; 1(1):24-8. PubMed ID: 6668481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
    Salazar R; Bissett D; Twelves C; Breimer L; DeMario M; Campbell S; Zhi J; Ritland S; Cassidy J
    Clin Cancer Res; 2004 Jul; 10(13):4374-82. PubMed ID: 15240525
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
    Cowens JW; Creaven PJ; Greco WR; Brenner DE; Tung Y; Ostro M; Pilkiewicz F; Ginsberg R; Petrelli N
    Cancer Res; 1993 Jun; 53(12):2796-802. PubMed ID: 8504422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
    Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
    Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BV
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [First phase in the clinical study of the antineoplastic antibiotic, carminomycin].
    Perevodchikova NI; Gorbunova VA; Lichinitser MR; Borisov VI; Alekseev NA
    Antibiotiki; 1975 Sep; (9):853-6. PubMed ID: 1101812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses.
    Earhart RH; Koeller JM; Davis HL
    Cancer Treat Rep; 1982 May; 66(5):1215-7. PubMed ID: 7083223
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
    Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
    Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study.
    Roh JK; Rha SY; Lee CI; Lee KH; Lee JJ; Shim HJ; Lee SD; Kim WB; Yang J; Kim SH; Lee MG
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):312-9. PubMed ID: 9660038
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
    Wynert WR; Harvey HA; Lipton A; Schweitzer J; White DS
    Cancer Treat Rep; 1982 Jun; 66(6):1303-6. PubMed ID: 7083234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NTP Toxicology and Carcinogenesis Studies of Isobutyl Nitrite (CAS No. 542-56-3) in F344 Rats and B6C3F1 Mice (Inhalation Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Jul; 448():1-302. PubMed ID: 12594527
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
    Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
    Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I study of L-alanosine using a daily x 3 schedule.
    Dosik GM; Stewart D; Valdivieso M; Burgess MA; Bodey GP
    Cancer Treat Rep; 1982 Jan; 66(1):73-6. PubMed ID: 7053269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.
    Stiff PJ; Sweet D; Kilton LJ; Johnson CM; Muntean B; Blough RR
    Med Pediatr Oncol; 1991; 19(2):126-8. PubMed ID: 2011097
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II trial of bisantrene in non-small cell lung cancer.
    Miller TP; Ahmann FR; Mackel C; Greenberg BR; Alberts DS
    Invest New Drugs; 1985; 3(4):393-5. PubMed ID: 4086247
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.
    Hutton JJ; Von Hoff DD; Kuhn J; Phillips J; Hersh M; Clark G
    Cancer Res; 1984 Sep; 44(9):4183-6. PubMed ID: 6204752
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer.
    Holmes FA; Esparza L; Yap HY; Buzdar AU; Blumenschein GR; Hortobagyi GN
    Cancer Chemother Pharmacol; 1986; 18(2):157-61. PubMed ID: 3791560
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study.
    Alberts DS; Mason-Liddil N; Green SJ; Cowan JD; Fletcher WS; Neilan B; Guy JT; Epstein RB
    Invest New Drugs; 1987; 5(3):289-92. PubMed ID: 3667164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II trial of bisantrene in advanced colorectal carcinoma.
    Ahmed T; Kemeny NE; Michaelson RA; Harper HD
    Cancer Treat Rep; 1983 Mar; 67(3):307-8. PubMed ID: 6831479
    [No Abstract]   [Full Text] [Related]  

  • 60. Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study.
    Vogelzang NJ; Lanzotti VJ; Muntean B; Blough RR
    Invest New Drugs; 1990 Aug; 8(3):313-5. PubMed ID: 2272771
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.